Introduction
Sphingolipids regulate various cellular processes linked to cancer development, progression, metastasis and resistance to therapy (1, 2) . Sphingolipids are synthesized de novo at the endoplasmic reticulum from serine and palmitoyl-CoA, which condense to form 3-ketosphinganine through the action of L-serine palmitoyl-CoA transferase (SPT), followed by rapid reduction to sphinganine (dhSph) by the 3-ketosphinganine reductase. Acyl-CoAs with various chain lengths are attached to sphinganine by chain length specific (dihydro)ceramide synthases (LASS1-6) [3] and dihydroceramide desaturase (DEGS) converts dihydroceramides (dhCer) to ceramides (Cers). The enzymes ceramidase and sphingosine kinase (SphK) 1 and 2 metabolize ceramides via sphingosine (Sph) to sphingosine-1-phosphate (S1P) (Figure 1 ).
The biologically active sphingolipids ceramide, Sph and dhSph play important and general roles in cellular regulation, such as apoptosis, cell cycle arrest and senescence (4) . Furthermore, some glycosylated (glycosylceramide) or phosphorylated (ceramide 1-phosphate) metabolites of ceramides are involved in signal transduction pathways leading to either inhibition of apoptosis or promotion of cell growth (5, 6) . Elevated glycosphingolipids (gangliosides) also correlate with augmented tumor invasiveness (7) . In contrast, S1P has a diverse role in signaling that depends on the synthesizing enzymes (SphK1 and SphK2) as well as the subcellular place of origin. S1P synthesized by SphK1 is involved in proliferative signaling (8) , whereas S1P synthesized by SphK2 is described as an antiproliferative and apoptotic mediator (9) . We recently observed contrasting data for the role of SphK2, in which MCF-7-SphK2-silenced xenografts grew slower in nude mice as compared with MCF-7-SphK2 wild-type xenografts (A.Weigert, S.Schiffmann, D.Sekar, S.Ley, S.Grösch, G.Geisslinger and B.Brüne submitted for publication).
Previous studies described different expression profiles of the sphingolipid metabolic enzymes in cancerous tissue relative to normal tissue. Kawamori et al. (10) and Johnson et al. (11) observed an upregulation of SphK1 in rat colon adenocarcinoma and lung cancer. A relevant role for SphK1 in carcinogenesis has also been shown in human prostate and breast cancer cells (12) (13) (14) . Furthermore, in human astrocytoma grade 4 tissue, the overexpression of SphK1, but not SphK2, correlates with poor patient survival (15) . In human prostate tumor tissues, the level of acid ceramidase is variable and seems to be relevant for proliferation, migration and as well as resistance to several chemotherapeutics (16, 17) . Koybasi et al. detected decreased LASS1 expression in human head and neck squamous cell carcinomas. In contrast, overexpression of LASS1 in head and neck squamous cell carcinomas cells leads to an increase of C 18:0 -Cer and subsequently to an inhibition of cell proliferation (18) . Taken together, these data indicate that enzymes of the sphingolipid metabolism such as SphK1, ceramidase and CerSs are involved in carcinogenesis in various tissues (colon, breast, prostate, head and neck). Alterations in the expression profile may be reflected in an altered sphingolipid level. Additionally, recent studies implied a distinct role for the ceramide N-acyl chain length, indicating that ceramides containing specific fatty acids play defined roles in cell physiology (19) (20) (21) (22) . In this study, we investigated the endogenous sphingolipid levels in breast cancer and normal tissue samples on both the transcriptional and/or translational levels.
Materials and methods

Reagents
The sphingolipid standards were purchased either from Avanti Polar Lipids (Alabaster, AL) or Matreya LLC (Pleasant Gap, PA). The antibodies LASS1 (goat polyclonal), LASS2 (goat polyclonal), LASS3 (goat polyclonal), LASS4 (goat polyclonal), LASS5 (goat polyclonal), SPT (goat polyclonal) and LASS6 (mouse monoclonal) were obtained from Santa Cruz Biotechnology (Heidelberg, Germany) and from Abnova GmbH (Heidelberg, Germany), whereas glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (mouse monoclonal) was obtained from Applied Biosystems/Ambion (Austin, TX).
Tissue samples
Malignant tissue, benign tissue and normal tissues of breast cancer patients were collected over 7 years with informed consent from patients undergoing surgical resection from the Department of Gynecology (Goethe-University, Frankfurt/Main, Germany). The protocol was approved from the local ethics committee. The samples were taken in the years 2001, 2003, 2005, 2006 and 2007. All tissue samples were stored at À80°C. Normal tissues (not benign, not malignant) were excised at least 1 cm away from the main tumor mass of the patients, but the tumor tissues from these patients were not included in this study. Therefore, the tumor tissues and the normal tissues originate from different patients (unpaired samples). Breast tissue samples were characterized according to standard pathology based on the estrogen receptor (ER) status as determined by ligand binding assays or by immunohistochemistry.
Determination of sphingolipid concentrations in tissue
Tissue samples (5-15 mg) used for quantification of sphingolipid concentrations were minced in phosphate-buffered saline on ice. A 10 ll tissue suspension (0.03 mg/ll) was added to 90 ll of freshly prechilled phosphatebuffered saline. Lipids were extracted in 700 ll of chloroform:methanol (7:1) after the addition of the internal standards (C 17:0 -Cer, C 17:0 -Sph, C 17:0 -S1P). The suspension was vortexed at 25°C for 1 min and centrifuged for 5 min at 25°C and 14 000 r.p.m. The organic phase was collected and the extraction step was repeated. The combined organic phases were dried under a stream of nitrogen and redissolved in 200 ll of methanol for quantitation. After liquid-liquid extraction, concentrations of C 16:0 -Cer, C 18:0 -Cer, C 20:0 -Cer, C 24:1 -Cer and C 24:0 -Cer and the internal standards were determined by liquid chromatography coupled with tandem mass spectrometry as described previously (23) . Chromatographic separation was accomplished under gradient conditions using a Luna C18 column (150 Â 2 mm ID, 5 lm particle size and 10 nm pore size; Phenomenex, Aschaffenburg, Germany). Precursor to product ion transitions of m/z 538 /264 for C 16 Suppression effects were assessed by extraction of tissue samples that were supplemented with 10 ng/ml internal standard in methanol. The mean peak areas of the samples supplemented with internal standard were compared with the mean peak area of the internal standard in methanol. An ion suppression effect was observed between 15 and 25% for the internal standard. Linearity of the calibration curve was proven for C 16:0 -Cer from 2 to 1000 ng/ml (3.7-1857 pmol/ml), for C 18:0 -Cer from 0.3 to 150 ng/ml (0.53-265 pmol/ml), for C 20:0 -Cer from 0.4 to 200 ng/ml (0.67-336 pmol/ml), for C 24:1 -Cer from 0.8 to 400 ng/ml (1.2-620 pmol/ml) and for C 24:0 -Cer from 1 to 1000 ng/ml (1.54-1537 pmol/ml). The coefficient of correlation for all measured sequences was at least 0.99. Variations in accuracy and intraday and interday precision (n 5 2 for each concentration in breast tissue) were ,15% over the whole range of calibration.
Real-time quantitative polymerase chain reaction Tumor tissue of patients with elevated and normal sphingolipid levels was investigated. The messenger RNA (mRNA) was isolated using a RNA isolation kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, with an optional DNAse step. Complementary DNA synthesis was performed using 200 ng mRNA and random hexamers of the Superscript III kit (Invitrogen GmbH, Karlsruhe, Germany). The expression levels of LASS1-6 and SPT were determined by Taqman TM analysis using SYBR Green kit (AbGene Limited, Epsom, UK) with an ABI Prism 7500 Sequence Detection System (Applied Biosystems). Relative expression of L-serine palmitoyl-CoA transferase long chain subunit 2 (SPTLC2) and CerS family genes was determined using the comparative cycle threshold method, normalizing relative values to the average expression of b-actin and GAPDH as housekeeping genes (24) . The designed primer sets were listed in supplement 2 (available at Carcinogenesis Online). Linearity of the assays was determined by serial dilutions of the templates for each primer set separately.
Western blot analysis
Frozen tissue was chopped with a mortar, suspended in lysate buffer [150 mM NaCl, 50 mM Tris, 1% NP40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% Triton-X 100, Roche complete (Roche, Mannheim, Germany) pH 7.4], sonicated and centrifuged (14 000g, 10 min, 4°C). The supernatant was stored at À80°C. Forty micrograms of the protein lysate were electroblotted. The antibodies used were diluted as follows: LASS1, 3, 4, 5, 6, SPT (1:100); LASS2 (1:300) and GAPDH (1:2000) .
Statistical analysis
First, the tissue concentrations of the various ceramides were compared by means of Friedman analysis of variance, with post-hoc Wilcoxon-Wilcox comparisons, a-corrected for multiple testing according to Bonferroni (BIAS software version 8.4, http://www.bias-onlinede.). Second, to analyze whether or not the ceramide concentrations differed between the tissue type subgroups (malignant, benign and normal), ceramide concentrations were submitted to Kruskal-Wallis analysis (25) , with the post-hoc a-corrected Dunn testing, separately for each ceramide. Third, at an exploratory level, ceramide tissue concentrations in the tumor type subgroups (malignant/benign) were compared between samples with respect to tumor size (large or small) by means of Kruskal-Wallis analysis (25) , with the post-hoc a-corrected Dunn testing, separately for each ceramide. Furthermore, also at an exploratory level, ceramide tissue concentrations in the malignant tissue subgroup were compared between samples with respect to lymph node (LN) status (positive or negative) and ER status (positive or negative) by means of Mann-Whitney U tests, Ã /y' indicate that S1P exhibits proliferative as well as proapoptotic potency depending on the location where it is synthesized as well as on the synthesizing enzyme (SphK1 or SphK2). CDase, ceramidase; CK, ceramide kinase; C1PP, ceramide-1-phosphate phosphatase; DEGS, dihydroceramide desaturase; FA, fatty acid; Gal, galactosidase, GCS, glucosylceramide synthase; KSR, 3-ketosphinganine reductase; SK1/2, sphingosine kinase1/2; S1PP, sphingosine-1-phosphate phosphatase.
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separately for each ceramide. Fourth, ceramide tissue concentrations were analyzed for correlations with SPT and LASS mRNA quantities using Spearman's q correlation analysis.
Results
Ceramide distribution in normal breast tissue
The aim of the study was to compare the endogenous ceramide levels in malignant and benign tissue with normal tissue to gain insight into the importance of ceramide deregulation in cancer development. Ceramide synthases act chain length specific. Therefore, we investigated ceramides of varying chain lengths in malignant, benign and normal tissues by liquid chromatography coupled with tandem mass spectrometry. To present a representative sphingolipid level, three to five different pieces of the tissue samples were employed and the sphingolipid level of each of these pieces was analyzed in duplicate. Figure 2 displays the mean ceramide levels of normal breast tissue normalized to 1 mg tissue (n 5 12). The Friedman test showed that the concentration of the various ceramides differ in part significantly from each other. It is obvious that C 16:0 -Cer [9.40 ± 2.8 (pmol/mg)], C 24:1 -Cer [2.80 ± 0.8 (pmol/mg)] and C 24:0 -Cer [3.49 ± 0.9 (pmol/ mg)] are the predominant ceramides in healthy breast tissue. The concentrations of Sph, dhSph, S1P and sphinganine-1-phosphate were under the detection limit in the selected tissue sample.
Analysis of ceramide levels of malignant, benign and normal breast tissue The levels of endogenous ceramides in 64 breast tumor tissues [malignant (n 5 43); benign (n 5 21)] were measured and compared with 12 samples of normal tissues. Malignant tumor tissues comprise the invasive breast cancer types 'invasive lobar mamma carcinoma' and 'invasive ductal mamma carcinoma' and the pre-stage breast cancer types 'lobar carcinoma in situ' and 'ductal carcinoma in situ'. The benign tissues include mastopathies and fibroadenomas. Figure  3A and Table I clearly exhibit that the total ceramide levels were significantly increased in malignant tissue as compared with the benign tissue and the normal tissue. The ceramide levels in the benign tissue were also increased as compared with normal tissue. A significant increase of ceramide levels in malignant tumor tissue versus the benign tissue points to a positive correlation of the ceramide level and disease severity (Table I ). An increase in ceramide levels in malignant and benign tissue versus normal tissue was observed for: C 16:0 -Cer, C 18:0 -Cer, C 20:0 -Cer, C 24:0 -Cer and C 24:1 -Cer (Table I) .
Next, we determined the extent to which ceramides were increased in tumor tissues. For this purpose, we related the mean values (for each specific ceramide) of the malignant and the benign samples to the corresponding mean value of the normal samples. The total ceramide level in malignant (benign) tumor tissue was 12.0-fold (4.0-fold) increased compared to normal tissue. The ceramide specific increase varied: 14.5-fold/4.4-fold (malignant/benign) for C 16:0 -Cer, 5.2-fold/5.1-fold for C 18:0 -Cer, 5.6-fold/3.9-fold for C 20:0 -Cer, 5.9-fold/2.3-fold for C 24:1 -Cer and 10.7-fold/3.5-fold for C 24:0 -Cer, respectively ( Figure 3B ). These data indicate that in malignant tumors the elevation of C 16:0 -Cer, C 24:1 -Cer and C 24:0 -Cer concentrations were more pronounced than that of other ceramides ( Table 1) .
Comparison of sphingolipid level and pathological parameters
To gain insight into the prognostic significance of the sphingolipid level, we investigated whether or not a relationship exists between an elevated sphingolipid level and various pathological parameters such as tumor size, LN status and hormone receptor status. The pathological parameters were not available for all patients, subgroups of patients from which the investigated parameters are known were selected. We missed the information concerning the tumor size of Ceramides are increased in breast cancer tissue six patients, the LN status of three patients, the ER status of five patients and the human epidermal growth factor receptor (HER-2/ neu) status of 12 patients. The number of patients that were analyzed is given in parentheses.
Tumor size: To exclude the possibility that the raised ceramide levels were a result of necrosis (mainly occurring in larger tumors), we compared the total ceramide levels of malignant and benign tissue with a diameter .2 cm (n 5 20) or 2 cm (n 5 21) (supplement 3A is available at Carcinogenesis Online). Malignant tumors disclose no significant correlation between tumor size and ceramide level, indicating that necrosis is not responsible for the raised ceramide level. In contrast, malignant tumors independent of tumor size and benign tumors with a diameter .2 cm (n 5 10) show a significant increase in ceramide level in comparison with benign tumors with smaller dimensions (n 5 7) ( Table I , supplement 3A is available at Carcinogenesis Online). These data indicate that the increased ceramide level correlates with disease severity.
LN status: A metastatic potential in colon cancer is discussed in the literature (26) for glycosylated ceramides. Therefore, we investigated whether an elevated ceramide level in tumors could be linked to the LN status. For malignant tumor tissue, the LN status was known from 40 patients [positive LN (n 5 16); negative LN (n 5 24)]. Figure 4A displays that the median of the total ceramide level, and specifically of C 16:0 -Cer, C 24:1 -Cer and C 24:0 -Cer, was increased in tumor tissues from patients with a positive LN status as compared with tumor tissues from patients with a negative LN status, whereas C 18:0 -Cer and C 20:0 -Cer were nearly unchanged. Interestingly, the increase of C 16:0 -Cer was significant. (Figure 4A , Table I ).
Grading status: Next, we investigated whether another important pathological parameter, the grading status of the malignant tumors, could be related to the sphingolipid status of the tumors. There was no significant difference between the ceramide levels of malignant tumor tissue ascribed to the G1-G2 status (n 5 23) and to malignant tumors ascribed to the G3-G4 status (n 5 20) (data not shown).
ER and HER-2/neu status:
Since the ER and the HER-2/neu status have important clinical implications in breast cancer, we checked whether the ceramide level could be linked to the ER or HER-2/neu receptor status. C 18:0 -Cer and C 20:0 -Cer are significantly elevated in ER positive malignant tumors, whereas C 16:0 -Cer, C 24:0 -Cer and C 24:1 -Cer are independent of the ER status ( Figure 4B ). However, the observed ceramide increase in malignant tumor tissue is independent of the HER-2/neu status (Table I ). There was also no correlation between the various ceramide levels of malignant tumors and a HER-2/neu negative/ER negative status (data not shown).
The mRNA expression levels of SPT and LASS1-6 in breast tumor tissue In order to obtain insight into the enzymes of the sphingolipid pathway that contribute to the elevated ceramide levels, the mRNA levels of all ceramide synthases (LASS1-6) and SPT (see also Figure 1 ) were investigated using real-time quantitative polymerase chain reaction. The SPT consists of at least two subunits SPTLC1/SPTLC2. Both subunits are equally expressed in breast tissue (27) . Recently, a new subunit of the SPT, SPTLC3, with variable tissue expression was described (28) . We therefore investigated the mRNA level of both SPTLC2 and SPTLC3. We examined 10 samples of tumor tissues with elevated (n 5 4) and depressed (n 5 6) sphingolipid levels. The mRNA expression level of each LASS and SPT were normalized to the average expression level of ß-actin and GAPDH (supplement 4 is available at Carcinogenesis Online). The mRNA level of LASS1, LASS3 and SPTLC3 were below the quantification limit. The functionality of the primers, which were used for the quantitative polymerase chain reaction of LASS1 and LASS3 in the breast tumor tissue were tested with brain and prostate tissue as positive controls, where LASS1 and LASS3 are predominantly expressed (29-31). The specific ceramide levels were plotted against the various LASS and The ceramide levels are shown as mean ± SEM. The pathological parameters were not available for all patients. Those patients whose investigated parameters are known were selected. The number of patients that were analyzed is stated in column 2. Data were statistically analyzed using Kruskal-Wallis test with the post-hoc a-corrected Dunn test or the Mann-Whitney U test ( Ã P , 0.05, ÃÃ P , 0.01, ÃÃÃ P , 0.001). The samples that were compared with each other were marked with parentheses. There was no correlation between ceramide level and SPTLC2 mRNA level. However, SPTLC2 and LASS5 were elevated in patients 1 and 2, which exhibited an outstanding increased ceramide level (supplement 4 is available at Carcinogenesis Online).
The protein expression level of SPT and LASS in breast tumor tissue Next, we analyzed whether translational modifications also play a role in the altered sphingolipid level in cancerous tissue using western blot analysis. Unfortunately, the currently available antibodies of LASS1, LASS3, LASS4, LASS5, LASS6 and SPT are not specific; therefore, no reproducible western blot or immunohistochemical staining was obtainable. Only LASS2 was reasonably detectable (supplement 5B is available at Carcinogenesis Online). Tissue samples that were previously subjected to the expression analysis of the mRNA level were used for the determination of the protein expression level. Using histochemistry, we showed that the investigated tumor tissues consist predominantly of one cell type (supplement 5A is available at Carcinogenesis Online); therefore, we could exclude cell type specific differences in the expression pattern of the LASS's. The western blot analysis revealed a correlation between ceramide level and LASS2 expression (supplement 5B is available at Carcinogenesis Online).
Discussion
In this study, we could clearly show that the total endogenous ceramide level was significantly elevated in malignant (12-fold) and benign (4-fold) breast tissue as compared with normal tissue, indicating that elevation of sphingolipid levels correlates with disease status. This elevation in ceramide levels was rather unexpected because in vitro studies predominantly indicated that an increase in ceramides is associated with an induction of apoptosis and therefore primarily linked with anticarcinogenic effects. An elevated concentration of sphingomyelin, a metabolite of ceramide, was also observed in human cancerous cervical tissues compared with normal cervical tissue (32). In Kanto et al. (34) reported that supernatants of tumor cells enriched with ceramides C 16:0 -Cer and C 24:0 -Cer induce apoptosis in dendritic cells that helps tumor cells to escape from the immune surveillance system, indicating that an elevated ceramide level in tumor cells could also have tumor protective effects. Moreover, the increase of C 16:0 -ceramide, synthesized by CerS5 or CerS6, leads to an activation of telomerase activity that is linked to tumor promotion (35) . In contrary, C 18:0 -Cer synthesized by CerS1, which is not expressed in breast tissue, leads to an inhibition of telomerase activity (18, 35) . In the here investigated breast cancer tissues, we detected elevated levels of C 16:0 -Cer, C 24:1 -Cer and C 24:0 -Cer (Table I, Figure 3) . Interestingly, the ratio between However, we could not exclude that also S1P and C1P or other metabolites of ceramide are elevated in our tissue samples but due to low expression levels of these substances and the limited tissue amount we could not detect all sphingolipids in a sample; an objective of future studies.
Our and literature data raise the question: Are the increased ceramide levels rather an effect or a cause of malignancy? Today, we couldn't make a clear statement about this issue because our data are generated by a snap-reading method. We could not track the ceramide concentrations over the time during the development of tumors from benign to precancerous to cancerous tumors. Therefore, to elucidate whether the increased ceramide levels are a consequence or a cause of malignancy or both and whether this depends on the N-acyl chain length of the ceramides, further experiments are needed.
Using real-time polymerase chain reaction, we could confirm our liquid chromatography coupled with tandem mass spectrometry data, showing that the mRNA levels of LASS2, LASS4, LASS5 and LASS6 The circles indicate significant correlation coefficients (circles: P , 0.01, dotted circles P , 0.05). The mRNA expression level was analyzed using real-time polymerase chain reaction. The relative expression of LASS2, 4, 5, 6 and SPT mRNA was calculated using the average mRNA levels of ß-actin and GAPDH as 100% value. Data are mean ± SEM of two experiments performed in triplicate. Each point represents one patient. A total of 10 patients with various ceramide levels were chosen.
S. Schiffmann et al. are elevated in tumor samples with high ceramide levels. In greater details, we could assign each upregulated ceramide type to one or two specific LASS isoforms ( Figure 5 ). The data suggest that LASS2, which converts lignoceryl-CoA (C 24:0 -CoA) (30) to C 24:0 -Cer, also accept nervonyl-CoA (C 24:1 -CoA) as a substrate. These suggestive data, however, require substantiation from further in vitro experiments. In contrast, we found no correlation between the expression level of SPT, the first and rate-limiting enzyme in sphingolipid de novo synthesis, and upregulated ceramide levels. Recently, Panjarian et al. also demonstrated that an increase in ceramide levels in human leukemia as well as in human colon cancer cells was mediated by induction of sphingolipid de novo synthesis. The effect was independent of SPT expression and activity, but rather due to an increase in CerS activity (37) . In fibroblasts, the SPT translocates from the cytosol in quiescent cells to the nucleus in proliferating cells (38) . The translocation would allow the enzyme to match up with the substrate and thereby inducing its activity. Therefore, translocation processes of the SPT could contribute to the raised elevated ceramide levels in the tumor tissue. It is also possible that additionally posttranslational regulation processes modulate SPT activity. Last but not least, also an enhanced salvage pathway could contribute to an increase in ceramides. This has to be investigated in further studies.
Comparison of ceramide levels with pathological parameters revealed that in patients with LN metastasis C 16:0 -Cer was significantly elevated. In line with our findings, Kovbasnjuk et al. (26) demonstrated an increase of the glycosylated ceramide Gb 3 in metastatic colon cancer tissue. Unfortunately, the study failed to specify the chain length of the ceramide backbone. Since the ER status is an important diagnostic marker in breast cancer, it is noteworthy that we observed a significant increase of C 18:0 -Cer and C 20:0 -Cer levels in ER positive samples as compared with ER negative samples (Figure 4B ). This agrees with our previous findings where we could demonstrate by microarray analysis that the expression level of LASS4 and LASS6 are also ER status dependently regulated (14) .
Moreover, we checked whether ceramide levels could be related to the clinical outcome of patients. The follow-up data of 20 patients was known. Sixteen patients were without pathological findings and six patients had a recrudescence [malignant (n 5 5)/benign (n 5 1)]. These included the following secondary tumor types: ovarial carcinoma (n 5 1); mamma carcinoma (n 5 2); osteometastasis (n 5 1) and fibroadenoma (with a history of fibroadenoma) (n 5 1). Five of these patients exhibited an elevated total ceramide level in their primary breast tumor sample. Only one patient with osteometastasis recrudescence showed no increase in sphingolipid level in the primary tumor sample. Due to the low patient number, no statistical significance could be achieved, but these data point to a correlation between an increased sphingolipid level and a higher risk for recrudescence.
In conclusion, in this study, we could demonstrate that ceramides C 16:0 -Cer, C 24:1 -Cer and C 24:0 -Cer were significantly increased in malignant breast tumor tissues as compared with benign and normal tissues indicating that an increase in distinct ceramides correlates with the development of breast cancer. Furthermore, we observed a correlation between elevated ceramide levels and the ER status, whereas a raised C 16:0 -Cer level was associated with a metastatic LN status. 
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